Modulating CCTG repeat expansion toxicity in DM2 Drosophila model through TDP1 inhibition.

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Myotonic dystrophy type 2 (DM2) is an adult-onset genetic disorder caused by CCTG repeat expansions, leading to myotonia and muscle degeneration.
• Current treatments for DM2 are ineffective, necessitating the exploration of novel therapeutic targets.

Purpose of the Study:

• To identify novel therapeutic targets for myotonic dystrophy type 2 (DM2) through high-throughput chemical screening.
• To investigate the role of Tyrosyl-DNA phosphodiesterase 1 (TDP1) as a potential therapeutic intervention for DM2.

Main Methods:

• Conducted a high-throughput chemical screen of 2160 compounds to identify DM2 modifiers.
• Utilized genetic and pharmacological inhibition of TDP1 in DM2 models.
• Assessed motor functions, muscle degeneration, muscle fiber repair, and molecular pathology.

Main Results:

• Identified Tyrosyl-DNA phosphodiesterase 1 (TDP1) as a novel therapeutic target for DM2.
• Demonstrated that TDP1 inhibition improves motor function and ameliorates muscle degeneration.
• Observed repair of muscle fiber damage and normalization of molecular pathology following TDP1 inhibition.
• Showcased significant CCTG repeat contractions upon TDP1 inhibition, a key factor in DM2 pathology.

Conclusions:

• TDP1 inhibition represents a promising therapeutic strategy for myotonic dystrophy type 2 (DM2).
• Targeting TDP1 addresses the core mechanisms of CCTG repeat expansions and subsequent neuromuscular degeneration.
• The findings suggest potential broader applications of TDP1 inhibition in other repeat expansion disorders.